Stockscreener 앱 받기
1.56
6.12%
0.09
시간 외 거래:
1.55
-0.01
-0.64%
전일 마감가:
$1.47
열려 있는:
$1.48
하루 거래량:
2.26M
Relative Volume:
0.73
시가총액:
$417.89M
수익:
$236.20M
순이익/손실:
$-5.35M
주가수익비율:
-87.15
EPS:
-0.0179
순현금흐름:
$67.70M
1주 성능:
+13.04%
1개월 성능:
+6.85%
6개월 성능:
-44.09%
1년 성능:
-14.75%
1일 변동 폭
$1.47
$1.56
1주일 범위
$1.38
$1.56
52주 변동 폭
$1.14
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.56 | 375.03M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Leerink reiterates Akebia stock rating on regulatory precedent By Investing.com - Investing.com Australia
Akebia (AKBA) Initiates Phase 1 Trial for AKB-9090 Targeting Kid - GuruFocus
Akebia doses first patients in Phase 1 trial of AKB-9090 - Investing.com Canada
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - The Manila Times
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Yahoo Finance
Akebia starts human testing of drug for kidney injury after heart surgery - Stock Titan
Profit Review: Is Akebia Therapeutics Inc attractive for institutional investorsGDP Growth & Momentum Based Trading Ideas - baoquankhu1.vn
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research - MarketBeat
Sectors Review: Is Akebia Therapeutics Inc stock trending bullishWeekly Risk Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Block Trades: What is the next catalyst for Akebia Therapeutics IncQuarterly Profit Review & Consistent Growth Stock Picks - baoquankhu1.vn
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - marketscreener.com
BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia executives head to New York for Apr. 14 biotech investor meetings - Stock Titan
BTIG Reiterates Buy Rating on AKBA with $4.00 Price Target | AKB - GuruFocus
H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics (AKBA) - The Globe and Mail
Sell Signal: Does Akebia Therapeutics Inc offer margin of safetyMarket Trend Review & Smart Allocation Stock Tips - baoquankhu1.vn
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Fed Meeting: Is Akebia Therapeutics Incs ROIC above industry average2026 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) stock price, news, quote and history - Yahoo Finance UK
H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy By Investing.com - Investing.com Canada
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Yahoo Finance
Aug Sectors: What is the next catalyst for Akebia Therapeutics Inc2026 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D DaySlideshow (NASDAQ:AKBA) 2026-04-04 - Seeking Alpha
Institutional Sell-Offs and Quiet Insiders Reveal Weak Confidence Behind Akebia's Pipeline Promotion - Bitget
Akebia (AKBA) director granted 214,400 options at $1.41, 3-year vest - Stock Titan
Akebia (NASDAQ: AKBA) director Philip J. Vickers files initial Form 3 - Stock Titan
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Akebia Therapeutics Issues Inducement Grants With Stock Options for New Employees - geneonline.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Akebia's Research and Development Day May Confirm or Undermine Its Kidney Treatment Strategy - Bitget
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
AKBA: Vafseo and a robust pipeline drive growth, with major clinical milestones expected by 2027 - TradingView — Track All Markets
AKBA: Innovative kidney disease pipeline advances with major clinical and commercial catalysts ahead - tradingview.com
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets - MarketBeat
Akebia Therapeutics adds Philip Vickers to board of directors By Investing.com - Investing.com South Africa
Akebia Therapeutics Appoints Philip Vickers, Ph.D. to Board of Directors – Company Details and Nasdaq Listing (2026) - Minichart
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - Sahm
Akebia Therapeutics appoints biopharmaceutical leader Philip Vickers to its board of directors - marketscreener.com
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors - TradingView
Akebia Therapeutics (AKBA) appoints Philip Vickers to Board as Steven Gilman retires - Stock Titan
Akebia Therapeutics adds Philip Vickers to board of directors - Investing.com
AKBA.O PE Ratio & Valuation, Is AKBA.O Overvalued - Intellectia AI
AKBA Should I Buy - Intellectia AI
AKBA.O Technical Analysis & Stock Price Forecast - Intellectia AI
AKBA.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKBA.O Forecast — Price Prediction for 2026. Should I Buy AKBA.O? - intellectia.ai
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Insider Monkey
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.06%
1.05%
자본화:
|
볼륨(24시간):